Experiences from treatment-predictive KRAS testing; high mutation frequency in rectal cancers from females and concurrent mutations in the same tumor
Open Access
- 15 October 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Clinical Pathology
- Vol. 9 (1), 8
- https://doi.org/10.1186/1472-6890-9-8
Abstract
Background: KRAS mutations represent key alterations in colorectal cancer development and lead to constitutive EGFR signaling. Since EGFR inhibition represents a therapeutic strategy in advanced colorectal cancer, KRAS mutation analysis has quickly been introduced as a treatment-predictive test. Methods: We used a real-time PCR based method to determine KRAS mutations in 136 colorectal cancers with mutations identified in 53 (39%) tumors. Results: KRAS mutations were significantly more often found in rectal cancer (21/38, 55%) than in colon cancer (32/98, 33%) (P = 0.02). This finding was explained by marked differences mutation rates in female patients who showed mutations in 33% of the colon cancers and in 67% of the rectal cancers (P = 0.01). Concurrent KRAS mutations were identified in three tumors; two colorectal cancers harbored Gly12Asp/Gly13Asp and Gly12Cys/Gly13Asp and a third tumor carried Gly12Cys/Gly12Asp in an adenomatous component and additionally acquired Gly12Val in the invasive component. Conclusion: The demonstration of a particularly high KRAS mutation frequency among female rectal cancer patients suggests that this subset is the least likely to respond to anti-EGFR therapies, whereas the observation of concurrent KRAS mutations imply that repeated KRAS targeting may occur during tumor progression in a subset of colorectal cancers.Keywords
This publication has 18 references indexed in Scilit:
- American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody TherapyJournal of Clinical Oncology, 2009
- Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E contextMolecular Cancer, 2008
- APC and the three-hit hypothesisOncogene, 2008
- Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancerThe Lancet Oncology, 2008
- KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance programVirchows Archiv, 2008
- Chromosomal changes in colorectal adenomas: Relationship to gene mutations and potential for clinical utilityGenes, Chromosomes and Cancer, 2005
- Sensitive Sequencing Method for KRAS Mutation Detection by PyrosequencingThe Journal of Molecular Diagnostics, 2005
- Are there two sides to colorectal cancer?International Journal of Cancer, 2002
- Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ studyBritish Journal of Cancer, 2001
- Frequency and Clinicopathology Associations of K-ras Mutations in Colorectal Cancer in a Northeast Mexican PopulationDigestive Diseases, 1999